News

What if a cancer patient could receive life-saving cellular therapy within days of diagnosis rather...
2021 Cell & Gene Meeting on the Med organized by the Alliance for Regenerative Medicine, was held...
Greg Crescenzi Joins Kytopen as Chief Commercial Officer to Drive Discovery, Development and...
BioCentriq™, the New Jersey Innovation Institute’s cell and gene therapy development and...
Kytopen co-founder Professor Cullen Buie studied mechanical engineering, first at Ohio State, then...
MIT spin-out company Kytopen has engaged Cambridge Consultants to co-develop the first Flowfect™...
Kytopen, an MIT spin-out company, and Cambridge Consultants, part of Capgemini, announce the...
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Kytopen, a technology startup accelerating the discovery and...
Merck, a leading science and technology company, today announced the winners of its Advance Biotech...
IF THE GENETIC REVOLUTION HAS YET TO DELIVER FULLY ON ITS PROMISE, Cullen Buie, associate professor...